文献速递介入腹部SPECTCT

既往消融与疾病进展与肝细胞癌99mTc-MAA肿瘤/正常肝摄取比升高相关

Prior ablation and progression of disease correlate with higher tumor-to-normal liver 99mTc-MAA uptake ratio in hepatocellular carcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2022-11-07

本研究回顾性分析4年内93例肝细胞癌患者行90Y放射栓塞前99mTc-MAA肝动脉造影SPECT/CT的资料,计算肿瘤/正常肝摄取比(T:N),评估预测因素。结果显示平均T:N为2.52,既往消融史和因疾病进展行治疗与更高的T:N显著相关,较大肿瘤体积有T:N降低趋势。提示有消融史或疾病进展的患者可能更适合优先考虑放射栓塞。

要点

  • 既往消融史与T:N显著升高相关(3.39 vs 2.24,p=0.003)。
  • 因疾病进展行治疗与T:N显著升高相关(3.35 vs 2.14,p=0.001)。
  • 肿瘤较大者T:N有降低趋势(p=0.052),但未达统计学显著性。

诊断标准与关键数值

  • 平均T:N为2.52;有消融史者平均3.39 vs 无消融史2.24(p=0.003)。
  • 因疾病进展治疗者平均T:N 3.35 vs 非进展者2.14(p=0.001)。
  • 较大肿瘤体积与较低T:N趋势相关(p=0.052)。

临床应用与阅片要点

  • 在90Y放射栓塞术前评估中,应关注患者既往消融史和当前是否为疾病进展治疗。
  • 对于有消融史或疾病进展的患者,可预期更高的T:N,可能提示更适合放射栓塞。

局限性

  • 回顾性研究,样本量有限(93例),可能存在选择偏倚。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Factors affecting tumor-to-normal tissue ratio (T:N) have implications for patient selection, dosimetry, and outcomes when considering radioembolization for HCC. This study sought to evaluate patient, disease specific, and technical parameters that predict T:N as measured on planning pre-90Y radioembolization 99mTc-MAA scintigraphy for hepatocellular carcinoma (HCC).

METHODS: 99mTc-MAA hepatic angiography procedures with SPECT/CT over a 4-year period were reviewed. Data recorded included patient demographics, details of underlying liver disease, tumor size, history of prior treatments for HCC and technical parameters from angiography. Anatomic-based segmentation was performed in 93 cases for measurement of tumor and perfused liver volumes and SPECT counts. T:N were calculated and correlated with collected variables.

RESULTS: Mean calculated T:N was 2.52. History of prior ablation was significantly correlated with higher T:N (mean 3.39 vs 2.24, p = 0.003). Cases in which mapping was being performed for treatment of disease progression was significantly correlated with higher T:N (mean 3.35 vs 2.14, p = 0.001). Larger tumor size trended toward lower T:N (p = 0.052).

CONCLUSION: Patients with history of ablation and those undergoing treatment for disease progression have higher T:N and, therefore, could be considered for radioembolization preferentially over alternative treatments.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Patel, McNiel, Brunson, et al. Prior ablation and progression of disease correlate with higher tumor-to-normal liver 99mTc-MAA uptake ratio in hepatocellular carcinoma. Abdom Radiol (NY). 2022. PMID: 36344658. doi:10.1007/s00261-022-03718-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。